Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RZLT 
Rezolute Inc (RZLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RZLT (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 85.89% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 176.76M USD | Price to earnings Ratio - | 1Y Target Price 13.11 |
Price to earnings Ratio - | 1Y Target Price 13.11 | ||
Volume (30-day avg) 613596 | Beta 0.96 | 52 Weeks Range 2.22 - 6.19 | Updated Date 04/1/2025 |
52 Weeks Range 2.22 - 6.19 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.23 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.81% | Return on Equity (TTM) -74.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 80944736 | Price to Sales(TTM) - |
Enterprise Value 80944736 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.01 | Shares Outstanding 60535400 | Shares Floating 52832292 |
Shares Outstanding 60535400 | Shares Floating 52832292 | ||
Percent Insiders 13.5 | Percent Institutions 81.98 |
Analyst Ratings
Rating 4.7 | Target Price 13 | Buy 3 | Strong Buy 7 |
Buy 3 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rezolute Inc
Company Overview
History and Background
Rezolute, Inc. is a biopharmaceutical company focusing on the development of therapies for rare metabolic diseases. Founded in 2010, it has evolved from early-stage research into clinical development with a focus on congenital hyperinsulinism (CHI).
Core Business Areas
- Congenital Hyperinsulinism (CHI) Program: Developing RZ358, a monoclonal antibody for the treatment of CHI, a rare genetic disorder causing abnormally high insulin levels.
- Preclinical Stage Assets: Focusing on research into new treatments for metabolic disorders.
Leadership and Structure
The company is led by a management team with experience in biopharmaceuticals and clinical development. The structure consists of research, development, and administrative departments, overseen by a Board of Directors.
Top Products and Market Share
Key Offerings
- RZ358: A monoclonal antibody being developed for the treatment of congenital hyperinsulinism (CHI). It is currently in clinical trials. Market share is not applicable as it is not yet approved. Competitors include Diazoxide, Octreotide and surgical options.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Focus is shifting toward rare disease therapeutics.
Positioning
Rezolute is positioned as a niche player focusing on rare metabolic diseases, particularly CHI. Its competitive advantage lies in its targeted monoclonal antibody therapy.
Total Addressable Market (TAM)
The TAM for CHI is difficult to precisely quantify due to its rarity, but it is estimated to be in the hundreds of millions of dollars globally. Rezolute is attempting to capture a significant portion of this TAM with RZ358.
Upturn SWOT Analysis
Strengths
- Targeted therapy for a rare disease
- Potential for orphan drug designation and market exclusivity
- Experienced management team
Weaknesses
- Reliance on a single lead product candidate
- High cash burn rate
- Clinical trial risk and regulatory hurdles
Opportunities
- Potential expansion into other rare metabolic diseases
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results and regulatory approval
Threats
- Competition from other therapies or companies
- Clinical trial failures
- Regulatory setbacks and pricing pressures
Competitors and Market Share
Key Competitors
- ADMP
- EBS
- AMGN
Competitive Landscape
Rezolute faces competition from established pharmaceutical companies. Its advantage lies in its targeted approach and potential for orphan drug designation.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily characterized by progression through preclinical and clinical development stages.
Future Projections: Future growth depends on the successful development and commercialization of RZ358 and other pipeline products. Analyst estimates would be contingent on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing RZ358 through clinical trials and exploring potential partnerships.
Summary
Rezolute, Inc. is a high-risk, high-reward biopharmaceutical company focused on rare diseases. Its success hinges on the clinical development of RZ358 and other pipeline assets. Positive clinical trial data and regulatory approval are crucial for its future growth. Cash management and strategic partnerships are also important factors to watch. Given the current stage and lack of revenue, the company is a very speculative investment.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
EBS
Emergent Biosolutions Inc
EBS
Emergent Biosolutions Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports (FactSet, Bloomberg)
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biopharmaceutical companies involves significant risks, including clinical trial failures, regulatory setbacks, and market volatility.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rezolute Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-05-01 | Founder, CEO, Principal Financial Officer & Acting Chairman of the Board Mr. Nevan Charles Elam J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://www.rezolutebio.com |
Full time employees 64 | Website https://www.rezolutebio.com | ||
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.